Healthcare
AI-powered clinical trials and patient-care program begins in Abu Dhabi
AstraZeneca and Oracle will test AI for diagnosis, clinical-trial matching, drug-safety monitoring, and evidence generation, starting with hypertension in Abu Dhabi.
The collaboration between AstraZeneca, Oracle, and M42 is intended to address several operational problems in healthcare: delayed diagnosis, lengthy referral pathways, and difficulty identifying patients eligible for clinical trials. The proposed tools will combine scientific and therapeutic expertise with cloud, analytics, health-data, and clinical-workflow capabilities. In Abu Dhabi, the initial focus is on patients with uncontrolled hypertension and on improving recruitment into related trials. The companies said future projects are planned across the United States, Europe, and the Middle East. The initiative is notable for treating AI as an infrastructure layer linking patient care, research recruitment, and evidence generation.
Original source: EMEA Outlook